Published :
Tables : 44
Figures : 40
Category : Healthcare
No. of Pages : 245
Report Code : HC-1143
Assisted Reproductive Technology Market Overview: Delayed childbearing is one of the dominant factors for increasing the adoption of assisted reproductive technology. Numerous initiatives such as the Asia Pacific Initiative on Reproduction (ASPIRE), an exclusive task force of scientists and clinicians, engaged infertility management and ART in the region should support industry growth. However, the high cost associated with ART treatment will hamper industry expansion to a certain extent over the coming years. Procedures such as in-vitro fertilization are offered at low cost in developing countries such as India, hence many people having trouble with getting or staying pregnant opt for this treatment in developing countries, leading to business growth. Growing awareness about ART procedure and its success rates will further lead to industry growth during the forecast period. Hospital end-use segment accounted for major market share. Rising prevalence of infertility problems coupled with growing awareness about assisted reproductive technology and its success rate should drive segment growth during the forecast period. According to CDC data, around fifteen states in the U.S. provide insurance coverage for infertility treatment that should positively impact market growth. Europe dominated the market due to the rise in infertility rate, rising awareness among people for fertility treatment, technological advancements and government initiatives. In 2014, CDC developed a national public health action plan for detection, improved efficacy of safe treatment, and prevention of infertility. The Barcelona summit suggested the establishment of an expert group to solve demographic issues, increase the childcare facilities and acceptance of parent IVF procedure for clinical trials. Market Segmentation: By Procedure • Fresh donor • Fresh Non-donor • Frozen Donor • Frozen Nondonor • Embryo/Egg Banking By Technology • In-vitro fertilization (IVF) o IVF with Intracytoplasmic Sperm Injection (ICSI) o IVF without Intracytoplasmic Sperm Injection (ICSI) • Artificial Insemination - Intrauterine Insemination (AI-IUI) • Frozen Embryo Replacement (FER) • Ovulation Induction (OI) • Donor Conception • Gamete Intrafallopian Transfer (GIFT) • Preimplantation Genetic Diagnosis (PGD) • Surrogacy By Diagnosis • Ovulation Testing • Hysterosalpingography • Ovarian Reserve Testing • Genetic Testing • Other hormone testing • Imaging tests By End User • Hospitals & Clinics • Ambulatory Surgical Centers • Diagnostic Centers • Gynecology Centers • Feminist Health Centers • IVF Centers By Region • North America • Europe • Asia Pacific • Latin America • MEA Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants Company Present in the market • Thermo Fisher Scientific, Inc. • Genea Limited • Cook Medical • Nidacon International AB • OvaScience Inc. • Vitro Life • Cooper Surgical Inc. • Merck • IVFtech ApS • Irvine scientific • Hamilton Thorne • Cosmos Biomedical • Microm UK Ltd. • Origio • Cryolab Ltd. • Parallabs • European Sperm Bank • Bloom IVF Centre • Ferring Pharmaceuticals FutureWise Takeaways • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Assisted Reproductive Technology Market By Procedure, By Technology, By Diagnosis, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Delayed childbearing is one of the dominant factors for increasing the adoption of assisted reproductive technology. Numerous initiatives such as the Asia Pacific Initiative on Reproduction (ASPIRE), an exclusive task force of scientists and clinicians, engaged infertility management and ART in the region should support industry growth. However, the high cost associated with ART treatment will hamper industry expansion to a certain extent over the coming years.
Procedures such as in-vitro fertilization are offered at low cost in developing countries such as India, hence many people having trouble with getting or staying pregnant opt for this treatment in developing countries, leading to business growth. Growing awareness about ART procedure and its success rates will further lead to industry growth during the forecast period.
Hospital end-use segment accounted for major market share. Rising prevalence of infertility problems coupled with growing awareness about assisted reproductive technology and its success rate should drive segment growth during the forecast period. According to CDC data, around fifteen states in the U.S. provide insurance coverage for infertility treatment that should positively impact market growth.
Europe dominated the market due to the rise in infertility rate, rising awareness among people for fertility treatment, technological advancements and government initiatives. In 2014, CDC developed a national public health action plan for detection, improved efficacy of safe treatment, and prevention of infertility. The Barcelona summit suggested the establishment of an expert group to solve demographic issues, increase the childcare facilities and acceptance of parent IVF procedure for clinical trials.
Market Segmentation:
By Procedure
• Fresh donor
• Fresh Non-donor
• Frozen Donor
• Frozen Nondonor
• Embryo/Egg Banking
By Technology
• In-vitro fertilization (IVF)
o IVF with Intracytoplasmic Sperm Injection (ICSI)
o IVF without Intracytoplasmic Sperm Injection (ICSI)
• Artificial Insemination - Intrauterine Insemination (AI-IUI)
• Frozen Embryo Replacement (FER)
• Ovulation Induction (OI)
• Donor Conception
• Gamete Intrafallopian Transfer (GIFT)
• Preimplantation Genetic Diagnosis (PGD)
• Surrogacy By Diagnosis
• Ovulation Testing
• Hysterosalpingography
• Ovarian Reserve Testing
• Genetic Testing
• Other hormone testing
• Imaging tests
By End User
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers
• Gynecology Centers
• Feminist Health Centers
• IVF Centers
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• MEA
Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
Company Present in the market
• Thermo Fisher Scientific, Inc.
• Genea Limited
• Cook Medical
• Nidacon International AB
• OvaScience Inc.
• Vitro Life
• Cooper Surgical Inc.
• Merck
• IVFtech ApS
• Irvine scientific
• Hamilton Thorne
• Cosmos Biomedical
• Microm UK Ltd.
• Origio
• Cryolab Ltd.
• Parallabs
• European Sperm Bank
• Bloom IVF Centre
• Ferring Pharmaceuticals
FutureWise Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the Assisted Reproductive Technology Market By Procedure, By Technology, By Diagnosis, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Technologyology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Assisted Reproductive Technology Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Assisted Reproductive Technology Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Assisted Reproductive Technology Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Assisted Reproductive Technology Market, By Procedure Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Fresh donor 7.2. Fresh Non-donor 7.3. Frozen Donor 7.4. Frozen Nondonor 7.5. Embryo/Egg Banking 8. Global Assisted Reproductive Technology Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. In-vitro fertilization (IVF) 8.1.1. IVF with Intracytoplasmic Sperm Injection (ICSI) 8.1.2. IVF without Intracytoplasmic Sperm Injection (ICSI) 8.2. Artificial Insemination - Intrauterine Insemination (AI-IUI) 8.3. Frozen Embryo Replacement (FER) 8.4. Ovulation Induction (OI) 8.5. Donor Conception 8.6. Gamete Intrafallopian Transfer (GIFT) 8.7. Preimplantation Genetic Diagnosis (PGD) 8.8. Surrogacy 9. Global Assisted Reproductive Technology Market, By Diagnosis Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Ovulation Testing 9.2. Hysterosalpingography 9.3. Ovarian Reserve Testing 9.4. Genetic Testing 9.5. Other hormone testing 9.6. Imaging tests 10. Global Assisted Reproductive Technology Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Hospitals & Clinics 10.2. Ambulatory Surgical Centers 10.3. Diagnostic Centers 10.4. Gynecology Centers 10.5. Feminist Health Centers 10.6. IVF Centers 11. North America Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Procedures Offered and Financial Layouts) 17.1. Thermo Fisher Scientific, Inc. 17.1.1. Company Overview 17.1.2. Mode of operation Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Genea Limited 17.2.1. Company Overview 17.2.2. Mode of operation Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Cook Medical 17.3.1. Company Overview 17.3.2. Mode of operation Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Nidacon International AB 17.4.1. Company Overview 17.4.2. Mode of operation Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. OvaScience Inc. 17.5.1. Company Overview 17.5.2. Mode of operation Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Vitro Life 17.6.1. Company Overview 17.6.2. Mode of operation Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Cooper Surgical Inc. 17.7.1. Company Overview 17.7.2. Mode of operation Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Merck 17.8.1. Company Overview 17.8.2. Mode of operation Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. IVFtech ApS 17.9.1. Company Overview 17.9.2. Mode of operation Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Irvine scientific 17.10.1. Company Overview 17.10.2. Mode of operation Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Hamilton Thorne 17.11.1. Company Overview 17.11.2. Technology Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Cosmos Biomedical 17.12.1. Company Overview 17.12.2. Technology Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Microm UK Ltd. 17.13.1. Company Overview 17.13.2. Technology Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Origio 17.14.1. Company Overview 17.14.2. Technology Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Cryolab Ltd. 17.15.1. Company Overview 17.15.2. Technology Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Parallabs 17.16.1. Company Overview 17.16.2. Technology Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 17.17.European Sperm Bank 17.17.1. Company Overview 17.17.2. Technology Portfolio 17.17.3. SWOT Analysis 17.17.4. Financial Overview 17.17.5. Strategic Overview 17.18.Bloom IVF Centre 17.18.1. Company Overview 17.18.2. Technology Portfolio 17.18.3. SWOT Analysis 17.18.4. Financial Overview 17.18.5. Strategic Overview 17.19.Ferring Pharmaceuticals 17.19.1. Company Overview 17.19.2. Technology Portfolio 17.19.3. SWOT Analysis 17.19.4. Financial Overview 17.19.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Technologyology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Global Assisted Reproductive Technology Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Assisted Reproductive Technology Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Assisted Reproductive Technology Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Assisted Reproductive Technology Market, By Procedure Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Fresh donor 7.2. Fresh Non-donor 7.3. Frozen Donor 7.4. Frozen Nondonor 7.5. Embryo/Egg Banking
8. Global Assisted Reproductive Technology Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. In-vitro fertilization (IVF) 8.1.1. IVF with Intracytoplasmic Sperm Injection (ICSI) 8.1.2. IVF without Intracytoplasmic Sperm Injection (ICSI) 8.2. Artificial Insemination - Intrauterine Insemination (AI-IUI) 8.3. Frozen Embryo Replacement (FER) 8.4. Ovulation Induction (OI) 8.5. Donor Conception 8.6. Gamete Intrafallopian Transfer (GIFT) 8.7. Preimplantation Genetic Diagnosis (PGD) 8.8. Surrogacy
9. Global Assisted Reproductive Technology Market, By Diagnosis Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Ovulation Testing 9.2. Hysterosalpingography 9.3. Ovarian Reserve Testing 9.4. Genetic Testing 9.5. Other hormone testing 9.6. Imaging tests
10. Global Assisted Reproductive Technology Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Hospitals & Clinics 10.2. Ambulatory Surgical Centers 10.3. Diagnostic Centers 10.4. Gynecology Centers 10.5. Feminist Health Centers 10.6. IVF Centers
11. North America Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027
12. Latin America Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027
13. Europe Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027
14. Asia Pacific Assisted Reproductive Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Procedures Offered and Financial Layouts) 17.1. Thermo Fisher Scientific, Inc. 17.1.1. Company Overview 17.1.2. Mode of operation Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Genea Limited 17.2.1. Company Overview 17.2.2. Mode of operation Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Cook Medical 17.3.1. Company Overview 17.3.2. Mode of operation Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Nidacon International AB 17.4.1. Company Overview 17.4.2. Mode of operation Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. OvaScience Inc. 17.5.1. Company Overview 17.5.2. Mode of operation Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Vitro Life 17.6.1. Company Overview 17.6.2. Mode of operation Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Cooper Surgical Inc. 17.7.1. Company Overview 17.7.2. Mode of operation Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Merck 17.8.1. Company Overview 17.8.2. Mode of operation Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. IVFtech ApS 17.9.1. Company Overview 17.9.2. Mode of operation Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Irvine scientific 17.10.1. Company Overview 17.10.2. Mode of operation Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Hamilton Thorne 17.11.1. Company Overview 17.11.2. Technology Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Cosmos Biomedical 17.12.1. Company Overview 17.12.2. Technology Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Microm UK Ltd. 17.13.1. Company Overview 17.13.2. Technology Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Origio 17.14.1. Company Overview 17.14.2. Technology Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Cryolab Ltd. 17.15.1. Company Overview 17.15.2. Technology Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Parallabs 17.16.1. Company Overview 17.16.2. Technology Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 17.17.European Sperm Bank 17.17.1. Company Overview 17.17.2. Technology Portfolio 17.17.3. SWOT Analysis 17.17.4. Financial Overview 17.17.5. Strategic Overview 17.18.Bloom IVF Centre 17.18.1. Company Overview 17.18.2. Technology Portfolio 17.18.3. SWOT Analysis 17.18.4. Financial Overview 17.18.5. Strategic Overview 17.19.Ferring Pharmaceuticals 17.19.1. Company Overview 17.19.2. Technology Portfolio 17.19.3. SWOT Analysis 17.19.4. Financial Overview 17.19.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics